Evidence map›Paper›PMID 27355210›Full record

ArticlePLoS neglected tropical diseases2016

Optimization of a Membrane Feeding Assay for Plasmodium vivax Infection in Anopheles albimanus.

Andrés F Vallejo, Kelly Rubiano, Andres Amado, Amy R Krystosik, Sócrates Herrera, Myriam Arévalo-Herrera

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Large-scale production ofFrontiers in tropical diseases · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Novel systems to study vector-pathogen interactions in malaria.Frontiers in cellular and infection microbiology · 2023
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Infectivity of Symptomatic Malaria Patients toFrontiers in cellular and infection microbiology · 2021
    Article
  19. Viability and Infectivity ofFrontiers in cellular and infection microbiology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Andrés F VallejoMalaria Vaccine and Drug Development Center (MVDC), Cali, Valle de Cauca, Colombia.
Kelly RubianoCaucaseco Scientific Research Center, Cali, Cali, Valle de Cauca, Colombia.
Andres AmadoCaucaseco Scientific Research Center, Cali, Cali, Valle de Cauca, Colombia.
Amy R KrystosikKent State University College of Public Health, Kent, Ohio, United States of America.
Sócrates HerreraCaucaseco Scientific Research Center, Cali, Cali, Valle de Cauca, Colombia.
Myriam Arévalo-HerreraCaucaseco Scientific Research Center, Cali, Cali, Valle de Cauca, Colombia.
Caucaseco Scientific Research Center · COKent State University · US

Funding

Vector Biology Research and Integrated Vector Management For Malaria ControlU19AI089702 · NIAID · CAUCASECO SCIENTIFIC RESEARCH CENTER · PI HERRERA VALENCIA, SOCRATES · 2010 to 2016
$11.5M
NIAID NIH HHS U19 AI089702
6 · The paper itself

Abstract

introductionIndividuals exposed to malaria infections for a long time develop immune responses capable of blocking Plasmodium transmission to mosquito vectors, potentially limiting parasite spreading in nature. Development of a malaria TB vaccine requires a better understanding of the mechanisms and main effectors responsible for transmission blocking (TB) responses. The lack of an in vitro culture system for Plasmodium vivax has been an important drawback for development of a standardized method to assess TB responses to this parasite. This study evaluated host, vector, and parasite factors that may influence Anopheles mosquito infection in order to develop an efficient and reliable assay to assess the TB immunity. METHODS/PRINCIPAL

findingsA total of 94 P. vivax infected patients were enrolled as parasite donors or subjects of direct mosquito feeding in two malaria endemic regions of Colombia (Tierralta, and Buenaventura). Parasite infectiousness was assessed by membrane feeding assay or direct feeding assay using laboratory reared Anopheles mosquitoes. Infection was measured by qPCR and by microscopically examining mosquito midguts at day 7 for the presence of oocysts. Best infectivity was attained in four day old mosquitoes fed at a density of 100 mosquitos/cage. Membrane feeding assays produced statistically significant better infections than direct feeding assays in parasite donors; cytokine profiles showed increased IFN-γ, TNF and IL-1 levels in non-infectious individuals. Mosquito infections and parasite maturation were more reliably assessed by PCR compared to microscopy.

conclusionsWe evaluated mosquito, parasite and host factors that may affect the outcome of parasite transmission as measured by artificial membrane feeding assays. Results have led us to conclude that: 1) optimal mosquito infectivity occurs with mosquitoes four days after emergence at a cage density of 100; 2) mosquito infectivity is best quantified by PCR as it may be underestimated by microscopy; 3) host cellular immune response did not appear to significantly affect mosquito infectivity; and 4) no statistically significant difference was observed in transmission between mosquitoes directly feeding on humans and artificial membrane feeding assays.

Indexed as

AdolescentAdultAnimalsAnophelesFeeding BehaviorFemaleHost-Parasite InteractionsHumansMalaria, VivaxMaleMembranes, ArtificialMiddle AgedMosquito VectorsPlasmodium vivaxYoung AdultMembranes, Artificial

Identifiers

PMID27355210
PMCPMC4927173
OpenAlexW2465568557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.